Atara Biotherapeutics (LTS:0HIY) FCF Margin % : -1,186.50% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Atara Biotherapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Atara Biotherapeutics's Free Cash Flow for the three months ended in Dec. 2023 was $-50.45 Mil. Atara Biotherapeutics's Revenue for the three months ended in Dec. 2023 was $4.25 Mil. Therefore, Atara Biotherapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was -1,186.50%.

As of today, Atara Biotherapeutics's current FCF Yield % is -242.84%.

The historical rank and industry rank for Atara Biotherapeutics's FCF Margin % or its related term are showing as below:

LTS:0HIY' s FCF Margin % Range Over the Past 10 Years
Min: -2265.25 Med: -1136.19 Max: -431.98
Current: -2265.25

During the past 12 years, the highest FCF Margin % of Atara Biotherapeutics was -431.98%. The lowest was -2265.25%. And the median was -1136.19%.

LTS:0HIY's FCF Margin % is ranked worse than
82.84% of 1037 companies
in the Biotechnology industry
Industry Median: -147.18 vs LTS:0HIY: -2265.25

Atara Biotherapeutics FCF Margin % Historical Data

The historical data trend for Atara Biotherapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atara Biotherapeutics FCF Margin % Chart

Atara Biotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-1,136.19

-431.98

-2,265.25

Atara Biotherapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-25,754.30	-3,167.05	-5,568.97	-2,414.73	-1,186.50

Competitive Comparison of Atara Biotherapeutics's FCF Margin %

For the Biotechnology subindustry, Atara Biotherapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atara Biotherapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's FCF Margin % falls into.

Atara Biotherapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Atara Biotherapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-194.2	/	8.573
	=	-2,265.25 %

Atara Biotherapeutics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-50.45	/	4.252
	=	-1,186.50 %

Atara Biotherapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Atara Biotherapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Atara Biotherapeutics (LTS:0HIY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atara Biotherapeutics Inc (LTS:0HIY) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

ATRA:USA AT2:Germany AT2:Germany

Address

2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA, USA, 91320

Website

https://www.atarabio.com

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Atara Biotherapeutics (LTS:0HIY) Headlines

No Headlines